Commentary on "Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism": A new role for plasminogen activator inhibitor-1-An inhibitor of fibrinolysis predicts future venous thromboembolic events and links them to obesity.
作者信息
Wojta Johann
机构信息
Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
出版信息
J Thromb Haemost. 2022 Jul;20(7):1559-1561. doi: 10.1111/jth.15728.
Abstract
摘要
相似文献
1
Commentary on "Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism": A new role for plasminogen activator inhibitor-1-An inhibitor of fibrinolysis predicts future venous thromboembolic events and links them to obesity.关于“纤溶酶原激活物抑制剂-1血浆水平升高与未来发生静脉血栓栓塞风险相关”的评论：纤溶酶原激活物抑制剂-1的新作用——一种纤维蛋白溶解抑制剂可预测未来静脉血栓栓塞事件并将其与肥胖联系起来。
J Thromb Haemost. 2022 Jul;20(7):1559-1561. doi: 10.1111/jth.15728.
2
Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.血浆纤溶酶原激活物抑制剂-1 水平升高与未来发生静脉血栓栓塞的风险相关。
J Thromb Haemost. 2022 Jul;20(7):1618-1626. doi: 10.1111/jth.15701. Epub 2022 Mar 25.
3
Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.靶向纤维蛋白溶解抑制治疗静脉血栓栓塞症：一种新兴治疗方法概述。
Circulation. 2024 Sep 10;150(11):884-898. doi: 10.1161/CIRCULATIONAHA.124.069728. Epub 2024 Sep 9.
4
Unexpected pulseless disease associated with recurrent venous thromboembolisms.
Clin Appl Thromb Hemost. 2009 Mar-Apr;15(2):239-40. doi: 10.1177/1076029607305782. Epub 2007 Dec 26.
5
[Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].[系统性红斑狼疮患者血浆凝血酶激活的纤溶抑制物、纤溶酶原激活物抑制剂-1及组织型纤溶酶原激活物水平与深静脉血栓形成的关系]
Zhonghua Yi Xue Za Zhi. 2023 Jun 6;103(21):1638-1642. doi: 10.3760/cma.j.cn112137-20220907-01888.
6
Plasminogen activator inhibitor-1 levels and polymorphisms.纤溶酶原激活物抑制剂-1水平与多态性
Arch Pathol Lab Med. 2002 Nov;126(11):1401-4. doi: 10.5858/2002-126-1401-PAILAP.
7
A hypofibrinolytic state in overweight patients with cerebral venous thrombosis and isolated intracranial hypertension.超重的脑静脉血栓形成和孤立性颅内高压患者的低纤溶状态。
J Neurol. 1999 Nov;246(11):1086-9. doi: 10.1007/s004150050517.
8
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.血浆纤溶酶原激活物抑制剂-1 和凝血酶激活的纤溶抑制物水平升高导致的血浆低纤溶与静脉血栓风险相关。
Blood. 2010 Jul 8;116(1):113-21. doi: 10.1182/blood-2010-02-267740. Epub 2010 Apr 12.
9
External pneumatic compression and fibrinolysis in abdominal surgery.腹部手术中的外部气动压迫与纤维蛋白溶解
J Vasc Surg. 2000 Sep;32(3):537-43. doi: 10.1067/mva.2000.107572.
10
Fibrinolytic activity of endothelial cells from different venous beds.不同静脉床内皮细胞的纤溶活性。
J Surg Res. 2015 Mar;194(1):297-303. doi: 10.1016/j.jss.2014.09.028. Epub 2014 Sep 28.
本文引用的文献
1
Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.血浆纤溶酶原激活物抑制剂-1 水平升高与未来发生静脉血栓栓塞的风险相关。
J Thromb Haemost. 2022 Jul;20(7):1618-1626. doi: 10.1111/jth.15701. Epub 2022 Mar 25.
2
A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.一种在多种蛋白酶抑制物中起作用的丝氨酸蛋白酶抑制剂：纤溶酶原激活物抑制剂-1在血栓炎症和心血管疾病中的核心作用
Front Cardiovasc Med. 2021 Apr 16;8:653655. doi: 10.3389/fcvm.2021.653655. eCollection 2021.
3
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1：纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
4
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.抗栓治疗与体重：欧洲心脏病学会血栓形成工作组专家立场文件
Eur Heart J. 2018 May 14;39(19):1672-1686f. doi: 10.1093/eurheartj/ehy066.
5
C-reactive protein, obesity, and the risk of arterial and venous thrombosis.C 反应蛋白、肥胖与动静脉血栓形成风险。
J Thromb Haemost. 2016 Aug;14(8):1561-71. doi: 10.1111/jth.13369. Epub 2016 Jun 22.
6
Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.纤溶酶原激活物抑制剂与心血管疾病风险：弗雷明汉心脏研究
Thromb Res. 2016 Apr;140:30-35. doi: 10.1016/j.thromres.2016.02.002. Epub 2016 Feb 3.
7
Basic mechanisms and regulation of fibrinolysis.纤维蛋白溶解的基本机制和调节。
J Thromb Haemost. 2015 Jun;13 Suppl 1:S98-105. doi: 10.1111/jth.12935.
8
Epidemiology of venous thromboembolism.静脉血栓栓塞症的流行病学
Nat Rev Cardiol. 2015 Aug;12(8):464-74. doi: 10.1038/nrcardio.2015.83. Epub 2015 Jun 16.
9
Thrombosis: a major contributor to the global disease burden.血栓形成：全球疾病负担的主要因素之一。
J Thromb Haemost. 2014 Oct;12(10):1580-90. doi: 10.1111/jth.12698.
10
Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.炎症标志物与静脉血栓栓塞事件：中风地理和种族差异原因（REGARDS）队列研究
J Thromb Haemost. 2014 Dec;12(12):1993-2001. doi: 10.1111/jth.12742. Epub 2014 Oct 31.
Zotero 插件